Therapeutic equivalence of mesalamine products

Reviews in Gastroenterological Disorders

Volumn 4, Issue 1, 2004, Pages 25-28

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Bioequivalence; Mesalamine; Pro drugs; Therapeutic equivalence

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG COATING; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTESTINE; PATIENT COMPLIANCE; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INTESTINAL ABSORPTION; MESALAMINE; PRODRUGS; THERAPEUTIC EQUIVALENCY;

EID: 1542725010     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in transplantation: A National Kidney Foundation White Paper. Am J Kidney Dis. 1999;33:389-397.
2. Reiffel JA. Issues in the use of generic antiar-rhythmic drugs. Curr Opinion Cardiol. 2001;16:23-29.
3. Food and Drug Administration Center for Drug Evaluation and Research. Approved Drug Products with Therapeutic Equivalence Evaluations. 23rd ed. May 2003. Available at: http://www.fda.gov/cder/ob/default.htm. Accessed July 10, 2003.
4. Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: An FDA regulatory overview. Pharmaceutical Res. 2001; 18:1645-1650.
5. Williams RL. Therapeutic equivalence of generic drugs response to National Association of Boards of Pharmacy. Center for Drug Evaluation and Research. Food and Drug Administration. April 16, 1997. Available at, www.fda.gov/cder/news/ntiletter.htm. Accessed June 4, 2003.
6. van Assche G, Baert F, de Reuck K et al. The role of aminosalicylates in the treatment of ulcerative colitis. Acta Gastro-Enterologica Belgica. 2003;65:196-199.
7. Wickersham RM (ed). Drug Facts and Comparisons. St. Louis: Facts & Comparisons; 2003.
8. Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: Are we comparing apples and oranges? Am J Gastroenterol. 2002;97:1283-1285.
9. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
10. Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalamine extended-release formulation. Aliment Pharmacol Ther. 2003;17:395-402.
11. Sandborn WJ, Hanauer SB. Systemic review: The phamacokinetic profiles of oral mesalamine formulations and mesalamine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42.
12. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002;97:2939-2941.
13. Hanauer SB. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol. 2003;98:215-216.
14. Cohen RD. The mesalamine wars heat up-enter balsalazide. Gastroenterology. 2003;124:574-575.
15. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalamine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198.